AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $266.69, with a market capitalization of 471.49B. The stock trades at a price-to-earnings (P/E) ratio of 75.14 and offers a dividend yield of 2.57%.
On 2026-10-06, AbbVie(ABBV) stock traded between a low of $260.62 and a high of $268.70. Shares are currently priced at $266.69, which is +2.3% above the low and -0.7% below the high.
AbbVie(ABBV) shares are trading with a volume of 4.32M, against a daily average of 4.24M.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $269.39 at its peak.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $269.39 at its peak.
ABBV News
Key Points One analyst sees expanded uses for Rinvoq and Skyrizi propelling AbbVie stock to as much as $315 per share. This bull case makes sense and could be...
AbbVie (ABBV Quick QuoteABBV - Free Report) , along with Genmab (GMAB Quick QuoteGMAB - Free Report) , announced positive top-line data from the phase...
AbbVie (ABBV -0.47%) is a top healthcare company that's been doing well this year, rising by 17% in value, which is better than the S&P 500 and its gains of aro...
Analyst ratings
75%
of 32 ratingsMore ABBV News
Scotiabank analyst Louise Chen raised the firm’s price target on AbbVie (ABBV) to $320 from $280 and keeps an Outperform rating on the shares. The increased pri...
Genmab and AbbVie reported that the Phase 3 EPCORE DLBCL-2 trial in newly diagnosed higher risk diffuse large B-cell lymphoma showed a 51% reduction in the risk...
AbbVie (ABBV Quick QuoteABBV - Free Report) closed the most recent trading day at $265.85, moving +1.15% from the previous trading session. The stock outp...
The company states: “Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2026 are expected to include acquired IPR&D and milestones e...
An announcement from Genmab ( (GMAB) ) is now available. Genmab and AbbVie reported on October 5, 2026, that their Phase 3 EPCORE DLBCL-2 trial showed epcorita...
Genmab A/S (GMAB) and AbbVie (ABBV) announced “positive” topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab,...
AbbVie (ABBV) just packed several pipeline updates into a short window, from FDA clearance of Parkinson's therapy JUVMO to fresh RINVOQ vitiligo data and new on...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.